The rare disease drug developer pulled in $145m through a round led by Pivotal BioVenture Partners and backed by Mitsui and Fidelity.

GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, which has now raised at least $166m to date.

OSI has returned to back Oxford indoor mapping spinout Navenio as the latter expands the market for its hospital workforce allocation system.

Johnson & Johnson Innovation – JJDC was among the investors in an $11.7m round for blood sealant technology developer Gatt Technologies.

John Öhd is to become Karolinska Institute's chief scientific officer on the back of 13 years of biotech industry expertise.

Holmusk, developer of a behavioural healthcare evidence platform, has completed a $21.5m round co-led by corporate venturing unit Optum Ventures.

The AstraZeneca cancer drug spinoff floated above its range in an upsized initial public offering and now has a market cap topping $2bn.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Genscript Biotech’s subsidiary Legend Biotech, which agreed to an investment worth nearly $151m from Eli Lilly and Johnson & Johnson last month, has filed to go public.